冠状动脉内注射阿昔单抗用于经皮冠状动脉介入治疗的系统评价被引量：1

Intracoronary abciximab administration for patients undergoing percutaneous coronary intervention:a meta-analysis of randomized trials

暂未订购

导出

摘要目的：系统评价阿昔单抗冠状动脉内应用与静脉内应用在经皮冠状动脉介入（PCI）治疗中的疗效和安全性。方法计算机检索PubMed、EMBASE、OVID、CBM、CNKI、VIP ，检索时间均从建库至2013年9月30日，并手工检索最近1年国内已发表的有关论文，纳入冠状动脉内应用阿昔单抗与静脉内应用阿昔单抗比较在PCI治疗中应用的所有随机对照试验（RCTs），并同时追索纳入研究的参考文献。按照Cochrane系统评价方法，由两名评价者独立对纳入研究的质量进行评价和资料提取后，采用RevMan5．1软件进行Meta分析。结果共纳入8个RCT ，10篇文献，包括4150例进行PCI治疗的患者。Meta分析结果显示：（1）阿昔单抗负荷剂量常规静脉给药组与阿昔单抗负荷剂量冠状动脉给药组相比，主要不良心脏事件（MACE）发生率和病死率在两组之间差异无统计学意义（OR＝0．78，95％ CI 0．54～1．14，P＝0．20）、（OR＝0．56，95％ CI 0．24～1．30，P＝0．18）。（2）与阿昔单抗负荷剂量静脉给药相比，阿昔单抗负荷剂量冠状动脉给药的严重出血事件发生率差异无统计学意义（OR＝1．26，95％ CI 0.78～2．02，P＝0．35）。结论与常规静脉给药相比，阿昔单抗负荷剂量冠状动脉内给药临床疗效相当，且不增加出血事件发生率。 Objective To systematically evaluate the efficacy and safety of intracoronary abciximab administration as compared to intravenous in percutaneous coronary intervention （PCI） .Methods A search was conducted in PubMed ,EMBASE ,OVID ,CBM , CNKI and VIP for the randomized controlled trials （RCTs）of intracoronary abciximab administration versus intravenous in PCI , from the date of their establishment to September 30 ,2013 ,and the domestic relevant papers published in recent 1 year were also searched manually ,the bibliographies of the included studies were searched too .According to the criteria of the cochrane Hand-book ,two reviewers evaluated the quality of the included RCTs and extracted data independently ,and then the extracted data were analyzed by using RevMan 5 .1 software .Results 8 RCTs involving 10 articles with 4 150 patients who treated with PCI were in-cluded .The results of meta-analysis showed that ：（1） Compared intravenous administration and intracoronary abciximab administra-tion ,there were no significant differences in the two groups for the major adverse cardiovascular event （MACE） and the mortality （OR=0 .78 ,95% CI 0 .54-1 .14 ,P=0 .20） ,（OR=0 .56 ,95% CI 0 .24-1 .30 ,P=0 .18） .（2）Compared with intravenous adminis-tration ,intracoronary abciximab administration were not associated with any excess of major bleeding complications ：（OR=1 .26 , 95% CI 0 .78-2 .02 ,P=0 .35） .Conclusion Compared with standard abciximab regimen of intravenous bolus ,intracoronary admin-istration had equivalent effects in clinical outcomes in patients undergoing PCI ,and did not increase the incidence of bleeding events .

作者尹晴张志刚马亚平李斌飞

机构地区中山大学附属第一医院麻醉科广东省中山市人民医院麻醉科深圳翰宇药业股份有限公司

出处《重庆医学》 CAS CSCD 北大核心 2013年第33期3995-3998,4001,共5页 Chongqing medicine

基金国家高技术研究发展计划"863计划"(2011ZX092011-006)

关键词阿昔单抗血小板糖蛋白Ⅱb IIIA受体拮抗剂经皮介入治疗冠状血管静脉 Meta分析 abciximab glycoprotein Ⅱb／IIIa inhibitors percutaneous coronary intervention coronary vessels veins Meta-analysis

分类号 R543 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献18

1Altay H, Pehlivanoglu S. Editorial: management of acute coronary syndromes in patients presenting without persis- tent ST-segment elevation., what has changed in the new european society of cardiology guideline[J]. Turk Kardiy- ol Dern Ars,2012,40(1):1-8.
2Harem CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in pa- tients presenting without persistent ST-segment eleva- tion. the Task Force for the management of acute coro- nary syndromes(ACS) in patients presenting without per- sistent ST-segment elevation of the european society of cardiology(ESC) [J]. G Ital Cardiol(Rome), 2012,13 (3) :171-228.
3Fernandez-Ortiz A, Pan M, Alfonso F, et al. Comments on the ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation, a report of the task force of the clinical practice guidelines committee of the spanish society of cardiology[J]. Rev Esp Cardiol,2012,65(2) : 125-130.
4Hamm CW,Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in pa- tients presenting without persistent ST-segment eleva- tion;The Task Force for the management of acute coro nary syndromes(ACS) in patients presenting without per- sistent ST-segment elevation of the european society of cardiology(ESC) [J]. Eur Heart J, 2011,32 (23) .. 2999 3054.
5Muller C. New ESC guidelines for the management of a- cute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Swiss Med Wkly, 2012,142 .. w13514.
6Mehilli J, Kastrati A, Schulz S, et al. Abciximab in pa- tients with acute ST-segment-elevation myocardial infarc- tion undergoing primary percutaneous coronary interven- tion after clopidogrel loading: a randomized double-blind triat[J]. Circulation, 2009,119 (14) : 1933-1940.
7Nakagawa Y, Nobuyoshi M, Yamaguchi T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized triaI(JEPPORT) [J]. Circ J, 2009,73 (1) : 145-151.
8Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non- ST-segment elevation acute coronary syndromes undergo ing percutaneous coronary intervention a{ter pre-treat ment with clopidogrel., results of the ISAR-REACT 2 ran domized trial[J]. Eur Heart J, 2008,29 (4) .. 455-461.
9Iversen A, Abildgaard U, Galloe A, et al. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment eleva- tion myocardial infarction(STEMI) patients reduces 30- day mortality and target vessel revascularization: a ran- domized trial[J]. J Interv Cardiol,2011,24(2) : 105-111.
10Eitel I, Friedenberger J, Fuernau G, et al. Intracoronary versus intravenous bolus abciximab application in pa tients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function, the randomised leipzig immediate percutaneous coronary in- tervention abciximab i. v. versus i. c. in ST-elevation myo- cardial infarction trial(LIPSIAbciximab-STEMI)[J]. Clin Res Cardiol, 2011,100(5) : 425-432.